G1 Therapeutics (GTHX) Hits New 12-Month Low at $15.13

Share on StockTwits

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $15.13 and last traded at $15.45, with a volume of 154346 shares traded. The stock had previously closed at $16.07.

A number of analysts have recently issued reports on GTHX shares. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, March 6th. BidaskClub raised G1 Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, February 12th. B. Riley started coverage on G1 Therapeutics in a research report on Thursday, February 7th. They set a “buy” rating and a $55.00 target price on the stock. Zacks Investment Research raised G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 12th. Finally, JPMorgan Chase & Co. lowered G1 Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $59.00 to $41.00 in a research report on Wednesday, January 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $66.00.

The firm has a market cap of $562.24 million, a price-to-earnings ratio of -5.89 and a beta of 2.37.

In other news, Director Cynthia Schwalm acquired 1,420 shares of the stock in a transaction that occurred on Wednesday, December 26th. The stock was purchased at an average cost of $18.45 per share, with a total value of $26,199.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.92% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in GTHX. Geode Capital Management LLC boosted its holdings in G1 Therapeutics by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 279,063 shares of the company’s stock worth $5,344,000 after purchasing an additional 26,098 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in G1 Therapeutics in the fourth quarter worth $1,570,000. FMR LLC boosted its holdings in G1 Therapeutics by 6.9% in the fourth quarter. FMR LLC now owns 5,577,754 shares of the company’s stock worth $106,814,000 after purchasing an additional 361,091 shares in the last quarter. Millennium Management LLC bought a new stake in G1 Therapeutics in the fourth quarter worth $269,000. Finally, Legal & General Group Plc boosted its holdings in G1 Therapeutics by 20.0% in the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock worth $78,000 after purchasing an additional 676 shares in the last quarter. 75.08% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “G1 Therapeutics (GTHX) Hits New 12-Month Low at $15.13” was first reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://weekherald.com/2019/03/22/g1-therapeutics-gthx-hits-new-12-month-low-at-15-13.html.

About G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Read More: NASDAQ Stock Market Explained

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.